Overview

Long-term Extension Study of BEMA™ Fentanyl

Status:
Completed

Trial end date:
2009-07-01

Target enrollment:

Participant gender:

Summary

This study is designed to provide continued access to BEMA Fentanyl for those subjects who previously participated in FEN-202 and who wish to continue using BEMA Fentanyl for the treatment of their breakthrough cancer pain.

Phase:

Phase 3

Details

Lead Sponsor:

BioDelivery Sciences International

Treatments:

Fentanyl